Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06111768
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Cardiorenal Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Receipt of 10mg oral dose of dapagliflozin once daily for three days

Study Details

The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.

Key Dates

Start date
May 30, 2024
Status verified
Dec 2025
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SGLT2i administration
    A 10 mg oral dose of dapagliflozin will be administered daily for three days.
  • No Intervention: Usual Care
    Subjects continue with usual care.

Primary Outcome Measure

Percentage of eligible versus consented patients [ Time Frame: From study initiation to study close (about 2 years) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale New Haven HospitalNew HavenConnecticut06520-

Find similar trials in New Haven, CT

By research site
Yale New Haven Hospital· New Haven, CT

Related Studies